Neuro-ophthalmology and Autoimmune Encephalitis (NODE) (NODE)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03872284|
Recruitment Status : Not yet recruiting
First Posted : March 13, 2019
Last Update Posted : August 8, 2019
|Condition or disease||Intervention/treatment|
|Autoimmune Encephalitis||Other: oculomotor movement recordings, neurovisual assessment|
|Study Type :||Observational|
|Estimated Enrollment :||70 participants|
|Official Title:||Study of Neuro-ophthalmology Disorders in Autoimmune Encephalitis (NODE)|
|Estimated Study Start Date :||October 2019|
|Estimated Primary Completion Date :||October 2026|
|Estimated Study Completion Date :||October 2026|
Patients in the study group have a diagnosis of autoimmune encephalitis, are 18 to 70 years old, and have no significant comorbidity such as psychiatric, neurological conditions and able to understand the aim of this study.
Other: oculomotor movement recordings, neurovisual assessment
Each participant will have a neurovisual assessment and an oculomotor movement recording with an eye tracker (infra red cameras).
- Percentage of patients presenting a neuro-ophthalmological abnormality. [ Time Frame: Day 0 ]A neuro-ophthalmological disorder is defined as an abnormality in the oculo-motor movement recording or/and the presence of a neurovisual impairment.
- Percentage of patients presenting neuro-ophthalmological abnormality. [ Time Frame: At 6 months if an abnormality is found ]A neuro-ophthalmological disorder is defined as an abnormality in the oculo-motor movement recording or/and the presence of a neurovisual impairment.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03872284
|Contact: Caroline Tilikete, Prof.||4 72 11 93 84 ext email@example.com|
|Principal Investigator:||Caroline Tilikete, Prof.||Department of neuro-ophthalmology, Pierre Wertheimer university hospital|